Cytokine regulation pathways controlling IL-10 and IL-12 production in antigen-presenting cells (IL-10/IL-12 APC regulation pathway)

The cytokine regulation pathways controlling IL-10 and IL-12 production in antigen-presenting cells (APCs) represent a fundamental axis of immune system modulation. APCs, including dendritic cells and macrophages, integrate signals from pathogens and the microenvironment to produce IL-12, which promotes pro-inflammatory Th1 cell differentiation, or IL-10, which exerts anti-inflammatory effects and suppresses IL-12 production (Saraiva & O'Garra, 2010, Nature Reviews Immunology). This reciprocal regulation is mediated by various signaling cascades, including the Toll-like receptor (TLR) pathways, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) system, and various mitogen-activated protein kinases (MAPKs) (Trinchieri, 2003, Nature Reviews Immunology). Dysregulation of this balance is a hallmark of many diseases; for instance, excessive IL-12 production is linked to autoimmune disorders like psoriasis and Crohn's disease, while elevated IL-10 can lead to chronic infections or tumor-mediated immune suppression (Iyer & Cheng, 2012, Journal of Interferon & Cytokine Research). Pharmacological targeting of this pathway includes the use of monoclonal antibodies like ustekinumab, which blocks the p40 subunit shared by IL-12 and IL-23, and small molecule JAK inhibitors that modulate downstream signaling (O'Shea et al., 2013, Nature Reviews Drug Discovery). Understanding these pathways is crucial for developing therapies that can precisely tune the immune response to either resolve chronic inflammation or enhance host defense against pathogens and tumors.

Other names

IL-10/IL-12 balanceAPC cytokine regulationTh1/Th2 regulatory axisInterleukin-10 and Interleukin-12 regulatory network

Modulation of cytokine signaling through the competitive inhibition of specific cytokine subunits (e.g., IL-12/23 p40) or the inhibition of intracellular signaling nodes such as Janus kinases (JAKs) to restore immune homeostasis and suppress pathological Th1/Th17 responses.